SC
CLRB icon

Stempoint Capital’s Cellectar Biosciences CLRB Stock Holding History

Stempoint Capital’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$987K Buy
+354,938
New +$993K 0.17% 71

Other funds holding CLRB

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

Stempoint Capital's CLRB Position: Q2 2026 in Review

Stempoint Capital opened a new position in Cellectar Biosciences (CLRB) in Q2 2026: 354,938 shares worth $987K. The stake represents 0.17% of the portfolio and ranks #71 among its holdings.

27 funds tracked by Wall St. Rank hold CLRB as of Q2 2026.

  • Stempoint Capital held 354,938 shares of Cellectar Biosciences worth $987K as of Q2 2026.
  • Cellectar Biosciences was a new Stempoint Capital position in Q2 2026.
  • Cellectar Biosciences made up 0.17% of Stempoint Capital's portfolio in Q2 2026, its #71 holding.
  • 27 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.